相似文献
1
Metastatic Renal Cell Cancer-Systemic Therapy.
Indian J Surg Oncol. 2018 Mar;9(1):97-104. doi: 10.1007/s13193-018-0721-2. Epub 2018 Jan 29.
2
Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
Front Oncol. 2022 Jun 8;12:892156. doi: 10.3389/fonc.2022.892156. eCollection 2022.
3
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study.
Clin Genitourin Cancer. 2022 Dec;20(6):533-542. doi: 10.1016/j.clgc.2022.07.010. Epub 2022 Jul 24.
4
Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.
Curr Oncol. 2018 Dec;25(6):e576-e584. doi: 10.3747/co.25.4103. Epub 2018 Dec 1.
5
First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Indian J Cancer. 2017 Oct-Dec;54(4):626-630. doi: 10.4103/ijc.IJC_380_17.
6
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126.
7
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Clin Genitourin Cancer. 2019 Feb;17(1):e32-e37. doi: 10.1016/j.clgc.2018.08.005. Epub 2018 Aug 28.
8
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
BMC Cancer. 2020 Jul 17;20(1):670. doi: 10.1186/s12885-020-07154-z.
9
Systemic therapy in metastatic renal cell carcinoma.
World J Urol. 2017 Feb;35(2):179-188. doi: 10.1007/s00345-016-1868-5. Epub 2016 Jun 9.
10
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
BMC Cancer. 2014 Aug 15;14:592. doi: 10.1186/1471-2407-14-592.
引用本文的文献
1
Clear Cell Renal Cell Carcinoma Spinal Metastases: Which Factors Matter to the Overall Survival? A 10-Year Experience of a High-Volume Tumor Spine Center.
Diagnostics (Basel). 2022 Oct 9;12(10):2442. doi: 10.3390/diagnostics12102442.
本文引用的文献
1
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
2
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
3
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15.
4
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21.
5
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.
6
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
7
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.
8
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18.
9
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
10
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.
Zotero 插件